Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers at Oxford University have received a prestigious Wellcome Innovator Grant for investigating the role of the pedunculopontine nucleus (PPN) – a brainstem nucleus – in human consciousness.

The study is a collaboration between Neurosurgery (Associate Professor Alex Green at the Nuffield Department of Surgical Sciences, NDS), Engineering (Professor Tim Denison at the Department of Engineering Science and the MRC Brain Network Dynamics Unit), and Neurology (Dr Damian Jenkins at the Nuffield Department of Clinical Neurosciences). It builds on pilot data from Dr Alceste Deli who, during her DPhil, has shown that PPN stimulation can alter sleep and arousal states.

The project will involve a 10-subject first-in-man clinical trial of PPN stimulation in patients with minimally conscious state (MCS) following brain injury (trauma or stroke) and will involve further development of a Deep Brain Stimulation investigational system called the ‘Picostim-DyNeuMo’ that was developed in a strategic collaboration between Professor Denison and Bioinduction, Ltd, a UK-based company developing implantable medical devices. The Picostim-DyNeuMo embeds instrumentation that enables novel clinical neuroscience using therapeutic neurostimulators.

The research team aim to identify biomarkers that signify arousal state, within the brain and on EEG, and to develop ‘closed-loop’ stimulation patterns that optimise increased arousal and improve sleep. The device will also take into account circadian rhythms that are often disrupted in patients with MCS.

The trial will be supported by the Surgical Intervention Trials Unit (SITU) at NDS (Ms Lucy Davies) and there will be an ethical component led by Professor Julian Savulescu at the Oxford Martin School. Dr Martin Gillies from NDS will also be involved in the running of the project.

 

The patients in the trial will be implanted with Deep Brain Stimulating electrodes (connected to an Implantable Pulse Generator) into the PPN (brainstem) and signals from the brain (local field potentials), EEG (electroencephalogram) and other signals, such as physical activity, will be used to control the system in a ‘closed loop’ manner.

Similar stories

Direct evidence of reduced NMDA receptors in people with form of encephalitis

NMDAR-antibody encephalitis is an autoimmune brain condition caused by patient’s own antibodies that bind to NMDA (N-Methyl-D-Aspartate) receptors in the synapses between nerve cells.

Director of MRC Brain Network Dynamics Unit appointed

From 2 January 2023, Professor Peter Magill will lead the Medical Research Council Brain Network Dynamics Unit (MRC BNDU) at the University of Oxford.

Jaideep Pandit honoured with RCoA Gold Medal

Congratulations are in order for Professor Jaideep Pandit, Professor of Anaesthesia and consultant anaesthetist, who has received the rarely awarded prestigious Gold Medal of the Royal College of Anaesthetists. Professor Pandit was a student and research fellow at DPAG and is now an Academic Visitor in the department; he is also a Fellow and Tutor in Medicine at St John's College.

Study reveals association between diagnosis of a neuropsychiatric condition and severe outcome from COVID-19 infection, and other severe acute respiratory infections

New research from the University of Oxford has shown an increased risk of severe illness and death from both COVID-19 and other severe respiratory infections, such as influenza and pneumonia, among people with a pre-existing mental health condition.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.